Novel therapeutic targets in esophageal cancer: Impact of chemokine receptor CXCR4

Future Oncology

Volumn 3, Issue 2, 2007, Pages 119-122

  Gockel, Ines ^a   Schimanski, Carl C ^a   Moehler, Markus ^a   Junginger, Theodor ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CELECOXIB; CETUXIMAB; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLAVOPIRIDOL; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MATUZUMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; STROMAL CELL DERIVED FACTOR 1; TOPOTECAN; TRASTUZUMAB; VASCULOTROPIN INHIBITOR;

ADJUVANT THERAPY; APOPTOSIS; CANCER INCIDENCE; CANCER INHIBITION; CANCER INVASION; CANCER MORTALITY; CELL CYCLE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; EDITORIAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; GROWTH REGULATION; HUMAN; INFLAMMATION; META ANALYSIS; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; CHEMOKINES, CXC; CYCLIN-DEPENDENT KINASES; DRUG DELIVERY SYSTEMS; ESOPHAGEAL NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; RECEPTORS, CXCR4;

EID: 34247153378     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.2.119     Document Type: Editorial

References (20)

1. Parkin DM: International variation. Oncogene 23, 6329-6340 (2004).
2. Blot WJ, McLaughlin JK: The changing epidemiology of esophageal cancer. Semin. Oncol. 26, 2-8 (1999).
3. Rouvelas I, Zeng W, Lindblad, Viklund P, Ye W, Lagergren J: Survival after surgery for esophageal cancer: a population-based study. Lancet Oncol. 6, 864-470 (2005).
4. Urschel JD, Vasan HB: A meta-analysis of randomized controlled trials that compared neo-adjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am. J. Surg. 185, 538-543 (2003).
5. Fiorica F, Di Bona D, Schepis F: Preoperative chemoradiotherapy for oesophageal cancer: a systemic review and meta-analysis. Gut 53, 925-930 (2004).
6. Huang SM, Harari PM: Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs 17, 259-269 (1999).
7. Baselga J, Pfister D, Cooper MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18, 904-914 (2000).
8. Aklilu M, Ilson DH: Targeted agents and esophageal cancer - the next step? Semin. Radiat. Oncol. 17, 62-69 (2007).
9. Ross JS, McKenna BJ: The HER-2/Neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 19, 554-568 (2001).
10. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011-1027 (2005).
11. Kleespies A, Guba M, Jauch KW, Bruns CJ: Vascular endothelial growth factor in esophageal cancer J. Surg. Oncol. 87, 95-104 (2004).
12. Presta LG, Chen H, O'Connor SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997).
13. Gorski DH, Beckett MA, Jaskowiak NT et al.: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374-3378 (1999).
14. Corley DA, Kerlikowske K, Verma R, Buffler P: Protective association of aspirin/NSAID's and esophageal cancer: a systematic review and metanalysis. Gastroenterology 124, 47-56 (2003).
15. Pillsbury HC 3rd, Webster WP, Rosenman J: Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Arch. Otolaryngol. Head Neck Surg. 112, 552-553 (1986).
16. Enzinger P, Mamon H, Choi NC: Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. ASCO Gastrointestinal Cancers 35, 59 (2004).
17. Schrump DS, Matthews W, Chen GA, Mixon A, Altorki NK: Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin. Cancer Res. 4, 2885-2890 (1998).
18. Minnich DJ, MacKay SLD, Camp ER, Contardo AM, Moldawer LL. Hochwald SN: Enhancement of chemotherapy response in esophageal carcinoma by inhibition of NF-κB. Proc. Am. Assoc. Cancer Res. 44, 1500 (2003).
19. Bramhall SR, Hallissey MT, Whiting J et al.: Marimastat as maintenance therapy for patiets with advanced gastric cancer: a randomised trial. Br. J. Cancer 86, 1864-1870 (2002).
20. Koishi K, Yoshikawa R, Tsujimura T et al.: Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer World J. Gastroenterol. 12, 7585-7590 (2006).